Amphastar Pharmaceuticals, Inc. (AMPH)

42,21 -0,56 (-1,31%) Alla chiusura: 04:00PM EDT

Amphastar Pharmaceuticals, Inc.

11570 6th Street
Rancho Cucamonga, CA 91730
United States
909 980 9484
https://www.amphastar.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.761

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ziping Luo Ph.D.	Chairman of the Board, Chief Scientist & COO	1,36M	N/D	1950
Dr. Yongfeng Zhang Ph.D.	Co-Founder, President, CEO, Chief Scientific Officer & Director	2M	N/D	1947
Mr. William J. Peters M.B.A.	CFO, Executive VP of Finance, Treasurer & Director	1,21M	7,17M	1968
Mr. Jacob Liawatidewi M.B.A.	Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director	880,1k	1,45M	1974
Mr. Rong Zhou M.S.	Senior Executive Vice President of Production	962,3k	997,35k	1959
Dan Dischner M.B.A.	Vice President of Human Resources & Corporate Communication	N/D	N/D	N/D
Tony Marrs M.B.A., M.P.H.	Senior VP of Regulatory Affairs & Clinical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Governance aziendale

L'ISS Governance QualityScore di Amphastar Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 9; diritti degli azionisti: 5; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.